Randomized phase II trial on mitomycin-C/Cisplatin ± KLT in heavily pretreated advanced breast cancer

American Journal of Chinese Medicine

Volumn 36, Issue 4, 2008, Pages 665-674

  Guo, H Y ^a   Cai, Y ^a   Yang, X M ^a   Wang, Z H ^a   Wang, J L ^a   Zhao, X M ^a   Li, J ^a   Hu, Xichun C ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast Cancer; Cisplatin; Mitomycin C; Phase II Study; Traditional Chinese Medicine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CHINESE DRUG; CISPLATIN; DEXAMETHASONE; DIAZEPAM; GRANISETRON; KANGLAITE; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MITOMYCIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 52049102035     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X08006132     Document Type: Article

References (30)

1. Blum, J.L., V. Dieras, P.M. Lo Russo, J. Horton, O. Rutman, A. Buzdar and B. Osterwalder. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768, 2001.
2. Bradner, W.T. Mitomycin C: A clinical update. Cancer Treat. Rev. 27: 35-50, 2001.
3. Cocconi, G., G. Bisagni, G. Ceci, B. Di Blasio, V. De Lisi, R. Passalacqua, A. Zadro, C. Boni, P. Morandi and L. Savoldi. Three new active cisplatin-containing combinations in the neo-adjuvant treatment of locally advanced and locally recurrent breast carcinoma: A randomized phase II trial. Breast Cancer Res. Treat. 56: 125-132, 1999.
4. Cui, Y, X.O. Shu, Y. Gao, W. Wen, Z.X. Ruan, F. Jin and W. Zheng. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res. Treat. 85: 263-270, 2004.
5. Cullen, M.H., L.J. Billingham, C.M. Woodroffe, A.D. Chetiyawardana, N.H. Gower, R. Joshi, D.R. Ferry, R.M. Rudd, S.G. Spiro, J.E. Cook, C. Trask, E. Bessell, C.K. Connolly, J. Tobias and R.L. Souhami. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. 17: 3188-3194, 1999.
6. Dong, Q.H., X. Zhong and S. Zheng. Effect of Kanglaite injection oncyclooxygenase activity in lung carcinoma A549 cell. Zhongguo Zhong Yao Za Zhi (Chin.) 30: 1621-1623, 1633, 2005.
7. Fumoleau, P, J.L. Blum and P. Reichardt. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 98: 1325-1326, 2003.
8. Gandara, D.R., E.A. Perez, H. Wold, V. Caggiano, M. Malec, D.K. Ahn, F. Meyers and R.W. Carlson. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 27: 243-247, 1990.
9. Garrone, O., E. Principe, M. Occelli, M. Mercuri, G. Numico, C. Granetto, G. Di Costanzo, P.D. Rattazzi and M. Merlano. A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer. Anticancer Drugs 15: 23-27, 2004.
10. Hortobagyi G.N. Mitomycin: Its evolving role in the treatment of breast cancer. Oncology 50(Suppl 1): 1-8, 1993.
11. Hu, Y., H. Liang, W.K. Gong, Z.F. Xu and Q.L. Zou. The effect of kanglaite injection (KLT) on the proliferation and telomerase activity of rat mesangial cells. Zhongguo Zhong Yao Za Zhi (Chin.) 30: 450-453, 2005.
12. Hu, X.C., H. Guo, X. Zhao, Z. Wang, X. Yang, S. Leaw and J. Li. Phase II study of mitomycin-C and cisplatin in heavily pretreated advanced breast cancer. Chin.-German J. Clin. Oncol. 5: 442-445, 2006.
13. Jiang, J., V. Slivova, K. Harvey, T. Valachovicova and D. Sliva. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr. Cancer 49: 209-216, 2004.
14. Li, D. The anticancer drug Kang-Lai-Te emulsion for infusion. Vestn. Ross. Akad. Med. Nauk. (Russian) 9: 32-37, 2005.
15. Mavroudis, D., N. Malamos, A. Alexopoulos, C. Kourousis, S. Agelaki, E. Sarra, A. Potamianou, C. Kosmas, G. Rigatos, T. Giannakakis, K. Kalbakis, F. Apostolaki, J. Vlachonicolis, S. Kakolyris, G. Samonis and V. Georgoulias. Salvage chemotherapy in anthracycline pre-treated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann. Oncol. 10: 211-215, 1999.
16. Miller, A.B., B. Hoogstraten, M. Staquet and A. Winkler. Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
17. Nabholtz, J.M., H.J. Senn, W.R. Bezwoda, D. Melnychuk, L. Deschênes, J. Douma, T.A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W. Nortier, D.J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J.Y. Genot, P.S. Hupperets, F. Pannuti, D. Skarlos, E.M. Tomiak, M. Murawsky, M. Alakl and M. Aapro. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 17: 1413-1424, 1999.
18. O'Shaughnessy, J.A., R.S. Clark, J.L. Blum, R.G. Mennel, D. Snyder, Z. Ye, A.M. Liepa, A.S. Melemed and D.A. Yardley. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin. Breast Cancer 6: 143-149, 2005.
19. Perez, E.A., G. Lerzo, X. Pivot, E. Thomas, L. Vahdat, L. Bosserman, P. Viens, C. Cai, B. Mullaney, R. Peck and G.N. Hortobagyi. Efficacy and safety of ixahepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25: 3407-3414, 2007.
20. Reichardt, P., G. Von Minckwitz, P.C. Thuss-Patience, W. Jonat, H. Kolbl, F. Janicke, D.G. Kieback, W. Kuhn, A.E. Schindler, S. Mohrmann, M. Kaufmann and H.J. Luck. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol. 14: 1227-1233, 2003.
21. Saikawa, Y., T. Kubota, T.H. Kuo, S. Kase, T. Furukawa, H. Tanino, K. Ishibiki and M. Katajima. Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro. J. Surg. Oncol. 54: 98-102, 1993.
22. Seidman, A.D. Monotherapy options in the management of metastatic breast cancer. Semin. Oncol. 30: 6-10, 2003.
23. Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
24. Sledge, G.W. Jr., P.J. Sr. Loehrer, B.J. Roth and L.H. Einhorn. Cisplatin as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 6: 1811-1814, 1988.
25. Thuss-Patience, P.C., G. von Minckwitz, A. Kretzschmar, S. Loibl, G. Scnaller, B. Dörken and P. Reichardt. Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: A preliminary phase II study. Anticancer Drugs 14: 549-553, 2003.
26. Thyagarajan, A., J. Zhu and D. Sliva. Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells. Int. J. Oncol. 30: 963-969, 2007.
27. Vassilomanolakis, M., G. Koumakis, M. Demiri, J. Missitzis, V. Barbounis and A.P. Efremidis. Vinorelbine and cisplatin for metastatic breast cancer: A salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest. 21: 497-504, 2003.
28. Vorobiof, D.A., B.L. Rapoportb, M.R. Chasenc, C. Slabber, G. McMichael, R. Eek and C. Mohammed. First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: A multicentre phase II study. Breast 13: 219-226, 2004.
29. Wagenaar, H.C., S. Pecorelli, C. Mangioni, M.E. van der Burg, N. Rotmensz, A. Anastasopoulou, P. Zola, C.H. Veenhof, A.J. Lacave, J.P. Neijt, A.T. van Oosterom, N. Einhorn and J.B. Vermorken. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. Eur. J. Cancer. 37: 1624-1628, 2001.
30. Wu, L.Q., Y. Lu, H.J. Lu, Z.G. Zhao and M. Yang. Efficacy of intra-tumor injection of Kang-Lai-Te in treating transplanted hepatoma in rats. Hepatobiliary Pancreat. Dis. Int. 3: 580-584, 2004.